BRCA1 and ovarian cancer: As such, synthetic lethality is ideally suited to exploit the truncal loss-of-function alterations leading to CIN, and is best exemplified by the synthetic lethal targeting of BRCA1/2-deficient ovarian cancers with the PARP inhibitor, Olaparib (detailed above) [109].